MiR-451a attenuates doxorubicin resistance in lung cancer via suppressing epithelialmesenchymal transition (EMT) through targeting c-Myc

Publication date: May 2020Source: Biomedicine & Pharmacotherapy, Volume 125Author(s): Li Tao, Wang Shu-Ling, Hao Jing-Bo, Zhang Ying, Hu Rong, Liu Xiang-Qun, Cui Wen-Jie, Zhou Lin-Fu
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research